Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04682964
PHASE3

Bacteriophage Therapy in Tonsillitis

Sponsor: Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan

View on ClinicalTrials.gov

Summary

The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil mucosa. A total of 5 ml of PCL was inhaled for 10 minutes every 5 days. The drug causes the lysis of certain bacteria, including staphylococcus, enterococcus, streptococcus, enteropathogenic E. coli, Proteus vulgaris, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae and Klebsiella oxytoca. The choice of this drug was based on bacteriological studies.

Official title: Bacteriophage Therapy in Acute Tonsillitis

Key Details

Gender

All

Age Range

3 Years - 14 Years

Study Type

INTERVENTIONAL

Enrollment

128

Start Date

2020-10-02

Completion Date

2028-12-31

Last Updated

2025-05-21

Healthy Volunteers

No

Interventions

DRUG

Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.

Bacteriophage therapy using a liquid complex of pyobacteriophages (pyobacteriophage complex liquid - PСL). PСL was administered via nebulizer inhalation to irrigate the mucous membranes of the tonsils. In total, 5 ml of PCL was inhaled for up to 10 minutes once every 5 days.

Locations (1)

Tashkent Pediatric Medical Institute

Tashkent, Uzbekistan